Literature DB >> 12953027

Sodium removal during pre-dilution haemofiltration.

Salvatore Di Filippo1, Celestina Manzoni, Simeone Andrulli, Francesca Tentori, Francesco Locatelli.   

Abstract

BACKGROUND: Cardiovascular instability still affects a large percentage of uraemic patients undergoing extracorporeal substitutive treatments. Post-dilution haemofiltration has been reported to be a method for improving cardiovascular stability; however, the limited removal of small molecular weight solutes together with the need for high blood flow from the fistula greatly restrict the use of this treatment. To increase the solute clearances and to partially resolve the necessity for high blood flow, the replacement solution, in a quantity about double that used in post-dilution mode, can be administered in pre-dilution mode. A high vascular stability has also been observed for pre-dilution haemofiltration. Since the lower morbidity may be due to less sodium removal when compared with haemodialysis, it would be important to characterize the sodium transport in this kind of treatment.
METHODS: Nine patients underwent nine pre-dilution haemofiltration treatments (one for each patient) with on-line prepared substitution fluid.
RESULTS: As mean values, total (NaF(pw)) and ionized (NaE(pw)) plasma water sodium concentrations increased from 149.4 +/- 2.8 mEq/l to 151.1 +/- 2.4 mEq/l, and from 143.1 +/- 2.8 to 144.5 +/- 1.2 mEq/l, respectively, during the treatment, suggesting a hypotonic concentration of net ultrafiltrate. Plotting the difference between final and initial ionized plasma water concentrations (fNaE(pw) - iNaE(pw)) against the difference between initial plasma water values and ionized sodium concentration in the reinfusate (iNaE(pw) - NaE(R)), a significant negative correlation was found, with the regression line that intercepts the abscissa at the (iNaE(pw) - NaE(R)) value of 8.8 mEq/l; this means that to avoid changes in NaE(pw) in our patients, the NaE(R) should be lower than the iNaE(pw) by this amount. This is quite different from the theoretical value of approximately 4 mEq/l necessary to avoid changes in NaE(pw) during haemodialysis. The ratio between the total sodium concentration in the ultrafiltrate (NaF(uf)) and NaF(pw) (alpha) at the post-reinfusion site was 0.96 and decreased to 0.94 when NaF(pw) values at the pre-reinfusion site were considered. This last value is quite close to the theoretical alpha value of post-dilution haemofiltration.
CONCLUSION: As for post-dilution haemofiltration, less sodium removal, compared with haemodialysis, can partly explain the improved cardiovascular stability during pre-dilution haemofiltration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12953027     DOI: 10.1093/ndt/gfg1076

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD.

Authors:  Francesco Locatelli; Paolo Altieri; Simeone Andrulli; Piergiorgio Bolasco; Giovanna Sau; Luciano A Pedrini; Carlo Basile; Salvatore David; Mariano Feriani; Giovanni Montagna; Biagio Raffaele Di Iorio; Bruno Memoli; Raffaella Cravero; Giovanni Battaglia; Carmine Zoccali
Journal:  J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 10.121

2.  The Association between Intradialytic Hypertension and Metabolic Disorders in End Stage Renal Disease.

Authors:  Vaia D Raikou; Despina Kyriaki
Journal:  Int J Hypertens       Date:  2018-04-04       Impact factor: 2.420

3.  Effect of various dialysis modalities on intradialytic hemodynamics, tissue injury and patient discomfort in chronic dialysis patients: design of a randomized cross-over study (HOLLANT).

Authors:  Paul A Rootjes; Menso J Nubé; Camiel L M de Roij van Zuijdewijn; Gertrude Wijngaarden; Muriel P C Grooteman
Journal:  BMC Nephrol       Date:  2021-04-15       Impact factor: 2.388

4.  Valacyclovir Neurotoxicity and Nephrotoxicity in an Elderly Patient Complicated by Hyponatremia.

Authors:  Takuya Murakami; Tetsu Akimoto; Mari Okada; Erika Hishida; Taro Sugase; Atsushi Miki; Marina Kohara; Hiromichi Yoshizawa; Takahiro Masuda; Takahisa Kobayashi; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Drug Target Insights       Date:  2018-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.